Impacting society, creating change
Technologies developed at Ohio State are changing the world. Learn more about the startups that are a part of the Ohio State portfolio as of June 30, 2021, below.
Search for a Startup below
HDO Health is a medical device portfolio company dedicated to bringing life-saving technologies to the world that help prevent people from bleeding to death. The company's core values are to be heart-led, data-driven and outcome-focused and aims to provide the world with the most effective, affordable and easy-to-use junctional tourniquet to help prevent people who have suffered a junctional wound from bleeding to death.
Vitranu, Inc. is developing a Tunable Extended Release Capsule (TERCTM) for biologic pharmaceuticals delivered via intravitreal injection. The company uses novel electrospinning technology to produce a tiny, double-walled, tunable capsule that can be filled with either biologic or small molecule therapeutics.
Nanofiber Solutions is a regenerative medicine company developing a new class of implants for the $20B soft tissue/organ repair/regeneration market. Its electrospun nanofiber substrate technology is used to build off-the-shelf scaffolds critical in the development of life-saving and life-changing, tissue engineered implants. Nanofiber’s products are used as a means to increase stem cell expansion rates for cellular therapy companies working on personalized treatments.
Clarametyx Biosciences is combating the formidable challenge of persistent antibiotic-resistant infections through an innovative technology platform that targets the biofilm—a protective layer around bacteria—to enable a more effective immune response or antibiotic intervention. The Columbus, Ohio-based company is building a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections associated with biofilms. Its lead candidate, CMTX-001, is a humanized monoclonal antibody in preclinical development for hospital-acquired pneumonia.
Ischemic stroke, a condition where a clot blocks blood flow to the brain, affects approximately 700,000 people annually in the U.S. Ischemic strokes result in 140,000 deaths each year and are a leading cause of long-term disability. Rapid restoration of blood flow to the brain is the only medical intervention proven to improve outcomes but only approximately 15-20% of patients qualify for either of the two FDA approved treatments.